Patent search ap:("VERTEX PHARMA") AND inv:"KADIYALA IRINA NIKOLAEVNA" Page 1

1.

发明申请
PHARMACEUTICAL COMPOSITION OF (R)-1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXY PROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEROF 审中-公开
Title translation: （R）-1-（2,2-二氟苯并[D] [1,3]二氧杂环戊烯-5-基）-N-（1-（2,3-二羟基丙基）-6-氟-2- （1-羟基-2-甲基丙-2-炔基）-1H-吲哚-5-基）环丙烷甲酰胺及其施用

公开(公告)号：WO2012027247A3

公开(公告)日：2012-05-24

申请号：PCT/US2011048565

申请日：2011-08-22

Applicant: VERTEX PHARMA , ALARGOVA ROSSITZA GUEORGUIEVA , DUNBAR CRAIG ANTONY , KADIYALA IRINA NIKOLAEVNA

Inventor： ALARGOVA ROSSITZA GUEORGUIEVA , DUNBAR CRAIG ANTONY , KADIYALA IRINA NIKOLAEVNA

IPC: A61K9/20 , A61K31/404

CPC classification number: A61K31/404 , A61K9/1623 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/2077

Abstract: A pharmaceutical composition comprising Compound 1, (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2- methylpropan-2-yl)-lH-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.

Abstract translation: 包含化合物1，（R）-1-（2,2-二氟苯并[d] [1,3]间二氧杂环戊烯-5-基）-N-（1-（2,3-二羟丙基）-6-氟 -2-（1-羟基-2-甲基丙-2-基）-1H-吲哚-5-基）环丙烷甲酰胺和至少一种赋形剂，其选自填料，稀释剂，崩解剂，表面活性剂，助流剂和润滑剂，该组合物适合于有需要的患者口服给药以治疗CFTR介导的疾病例如囊性纤维化。用于治疗有需要的患者的方法包括给药化合物1的药物组合物也被公开。

2.

发明申请
PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIODIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF 审中-公开
Title translation: 3-（6-（1-（2,2-二氟苯并[D] [1,3]二氧杂环戊烯-5-基）环己基碳酰氧基）-3-甲基吡啶-2-基）苯甲酸的药物组合物及其施用

公开(公告)号：WO2011127241A3

公开(公告)日：2012-02-02

申请号：PCT/US2011031519

申请日：2011-04-07

Applicant: VERTEX PHARMA , VERWIJS MARINUS JACOBUS , ALARGOVA ROSSITZA GUEORGUIEVA , KAUSHIK RITU ROHIT , KADIYALA IRINA NIKOLAEVNA , YOUNG CHRISTOPHER RYAN

Inventor： VERWIJS MARINUS JACOBUS , ALARGOVA ROSSITZA GUEORGUIEVA , KAUSHIK RITU ROHIT , KADIYALA IRINA NIKOLAEVNA , YOUNG CHRISTOPHER RYAN

IPC: A61K9/16 , A61K9/20 , A61K9/28 , C07D213/75 , C07D405/12 , C07D405/14

CPC classification number: A61K31/443 , A61K9/0053 , A61K9/1682 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K31/47

Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2- difluorobenzo [d] [ 1,3 ] dioxol-5 -y1) cyclopropanecarboxamido)-3 -methylpyridin-2-y1)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Abstract translation: 包含化合物1（3-（6-（1-（2,2-二氟苯并[d] [1,3]二氧杂环戊烯-5-基）环丙烷甲酰氨基）-3-甲基吡啶-2-基）苯甲酸的药物组合物和至少一种选自：填料，稀释剂，崩解剂，表面活性剂，粘合剂，助流剂和润滑剂的赋形剂，所述组合物适合于有需要的患者口服给药以治疗CFTR介导的疾病，例如作为囊性纤维化。用于治疗有需要的患者的方法包括向患者施用化合物1的口服药物制剂。

3.

发明申请
CONTROLLED RELEASE FORMULATIONS 审中-公开
Title translation: 控制释放公式

公开(公告)号：WO2007142951A2

公开(公告)日：2007-12-13

申请号：PCT/US2007012715

申请日：2007-05-30

Applicant: VERTEX PHARMA , KADIYALA IRINA NIKOLAEVNA , LIN WU , HURTER PATRICIA

Inventor： KADIYALA IRINA NIKOLAEVNA , LIN WU , HURTER PATRICIA

CPC classification number: A61K9/1688 , A61K9/2077 , A61K9/2095 , A61K31/401

Abstract: The invention relates to a controlled release formulation for an oral cytokine inhibitor of interleukin-1 beta converting enzyme.

Abstract translation: 本发明涉及一种用于白细胞介素-1β转换酶的口服细胞因子抑制剂的控释制剂。

4.

发明公开
CRYSTALLINE FORMS OF C21H22CI2N4O2 审中-公开

公开(公告)号：EP3250562A4

公开(公告)日：2018-07-11

申请号：EP16744240

申请日：2016-01-29

Applicant: BIOMED VALLEY DISCOVERIES INC , VERTEX PHARMA

Inventor： DECRESCENZO GARY , WELSCH DEAN , VLAHOVA PETINKA I , BOERRIGTER STEPHAN X M , ARONOV ALEXANDER , KESHAVARZ-SHOKRI ALI , SCANGAS ALEXANDER N , STAVROPOULOS KATHY , LITTLER BENJAMIN , KADIYALA IRINA NIKOLAEVNA , ALARGOVA ROSSITZA GUEORGUIEVA

IPC: C07D401/04 , A61K31/4439 , A61K45/06 , A61P35/00

CPC classification number: C07D401/04 , A61K31/4439 , A61K45/06 , A61P35/00

Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

5.

发明专利
CO-CRYSTALS OF (S)-N-METHYL-8-(1-((2'-METHYL-[4,5'-BIPYRIMIDIN]-6-YL)AMINO)PROPAN-2-YL)QUINOLINE-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS 未知

公开(公告)号：CA2927631C

公开(公告)日：2022-05-17

申请号：CA2927631

申请日：2014-10-17

Applicant: VERTEX PHARMA

Inventor： KADIYALA IRINA NIKOLAEVNA , O'NEIL SIMON ADAM , STROHMEIER MARK , WALDO MICHAEL , NAVAMAL METTACHIT , STAVROPOULOS KATHY , MUDUNURI PRAVEEN , SONG BIN , VAN ALSTEN JOHN GREGG , NTI-ADDAE KWAME WIREDU , ZHANG YUEGANG

IPC: C07D401/14 , A61K31/506 , A61P35/00

Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.

6.

发明专利
UNA TABLETA PARA ADMINISTRACIÓN ORAL QUE COMPRENDE ÁCIDO 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-IL)CICLOPROPANCARBOXAMIDO)-3-METILPIRIDIN-2-IL)BENZOICO 未知

公开(公告)号：AR120065A2

公开(公告)日：2022-02-02

申请号：ARP200101884

申请日：2020-07-03

Applicant: VERTEX PHARMA

Inventor： VERWIJS MARINUS JACOBUS , ALARGOVA ROSSITZA GUEORGUIEVA , KAUSHIK RITU ROHIT , KADIYALA IRINA NIKOLAEVNA , YOUNG CHRISTOPHER

IPC: A61K31/443 , A61K9/00 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/28 , A61K31/47 , A61K45/06 , C07D405/12 , C07D405/14 , C07D451/02

Abstract: Una tableta para administración oral que comprende: a. 25 mg a 250 mg de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico (Compuesto 1) Forma I; b. un relleno; c. un disgregante; d. un surfactante; e. un lubricante y f. un aglutinante que es polivinilpirrolidona.

7.

发明专利
Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK 未知

公开(公告)号：ES2802296T3

公开(公告)日：2021-01-18

申请号：ES18188034

申请日：2014-10-17

Applicant: VERTEX PHARMA

Inventor： NTI-ADDAE KWAME , O'NEIL SIMON ADAM , ZHANG YUEGANG , MUDUNURI PRAVEEN , VAN ALSTEN JOHN GREGG , SONG BIN , STAVROPOULOS KATHY , STROHMEIER MARK , WALDO MICHAEL , NAVAMAL METTACHIT , KADIYALA IRINA NIKOLAEVNA

IPC: C07D401/14 , A61K31/506 , A61P35/00

Abstract: Un co-cristal que comprende un compuesto de fórmula **(Ver fórmula)** y un formador de co-cristal, en la que el formador de co-cristales es ácido adípico, en la que cada uno de R1 y R2 es independientemente hidrógeno o deuterio, para su uso en la potenciación de un régimen terapéutico para el tratamiento del cáncer, en la que el uso comprende administrar a un individuo que lo necesite una cantidad efectiva de dicho co-cristal, y en la que el régimen terapéutico es la radioterapia.